Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112417 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Yin-Shuang Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, B7-H1 Antigen, Curcumin, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Drug local delivery system that directly supply anti-cancer drugs to the tumor microenvironment (TME) results in excellent tumor control and minimizes side effects associated with the anti-cancer drugs. Immune checkpoint inhibitors (ICIs) have been the mainstay of cancer immunotherapy. However, the systemic administration of ICIs is accompanied by considerable immunotherapy-related toxicity. To explore whether an anti-PD-L1 antibody administered locally via a sustained-release gel-forming carrier retains its effective anticancer function while causing fewer colitis-like side effects, CT, a previously reported depot system, was used to locally deliver an anti-PD-L1 antibody together with curcumin to the TME in bladder cancer-bearing ulcerative colitis model mice. We showed that CT-mediated intratumoral coinjection of an anti-PD-L1 antibody and curcumin enabled sustained release of both the loaded anti-PD-L1 antibody and curcumin, which contributed to substantial anticancer effects with negligible side effects on the colons of the UC model mice. However, although the anti-PD-L1 antibody administered systemically synergized with the CT-mediated intratumoral delivery of curcumin in inhibiting tumour growth, colitis was significantly worsened by intraperitoneal administration of anti-PD-L1 antibody. These findings suggested that CT is a promising agent for the local delivery of anticancer drugs, as it can allow effective anticancer functions to be retained while sharply reducing the adverse side effects associated with the systemic administration of these drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.
- Department of Pathology, Jin Hua Municipal Central Hospital, Jin Hua, Zhejiang, China.
- Department of Pathology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.
- Department of Ultrasound, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.
- Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China; School of Food Science and Nutrition, Univer…
Zitieren
APA
Wang, Y. S., Zheng, A. H., Zhao, J. W., Gu, H. Y., Meng, Z. N., Chen, J. Y., Wang, F. W., Zhu, X. M., Chen, Y., Xu, S. C., Sun, L. T., Lai, W. F., Wu, G. Q., & Zhang, D. H. (2024). Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112417
Vancouver
Wang YS, Zheng AH, Zhao JW, Gu HY, Meng ZN, Chen JY, et al. Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112417
BibTeX
@article{Wang2024,
author = {Wang, Yin-Shuang and Zheng, Ai-Hong and Zhao, Jing-Wen and Gu, Hang-Yu and Meng, Zhuo-Nan and Chen, Jian-Yuan and Wang, Fu-Wei and Zhu, Xiu-Ming and Chen, Yuan and Xu, Song-Cheng and Sun, Li-Tao and Lai, Wing-Fu and Wu, Guo-Qing and Zhang, Da-Hong},
title = {Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112417}
}
EUVIMED